AZD5423 significantly attenuated the fall in FEV1 during the late asthmatic response ( both doses led to an 8.7 % fall ) versus placebo ( 14 % fall ) ( P < 0.05 ) with no effect of budesonide ( 12.5 % fall ) versus placebo ( P > 0.05 ) .